文献速递头颈外科

治疗前高MCV是非贫血头颈癌患者的不良预后标志

Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer.
PubMed 文献 · Laryngoscope · 2020-06-26

这项多中心回顾性队列研究纳入260例接受根治性器官保留治疗的III/IVA-B期头颈鳞癌患者,分析治疗前MCV、血红蛋白、血小板和 albumin 与生存的关系。调整混杂因素后,低血红蛋白者死亡风险高3.3倍(95%CI 2.26-4.81),高MCV者死亡风险高1.54倍(95%CI 1.06-2.24),且MCV的预后效应仅限于治疗前血红蛋白正常者。

要点

  • 治疗前贫血是III/IVA-B期HNSCC器官保留治疗患者的独立不良预后因素。
  • 治疗前高MCV是非贫血HNSCC患者总生存和无进展生存的独立不良预后因素。
  • 治疗前血小板计数和白蛋白浓度与生存无显著关联。

核心结论

  • 治疗前贫血和大细胞增多是接受器官保留治疗的HNSCC患者总生存和无进展生存较低的独立预测因素。

研究设计与样本

  • 多中心回顾性队列研究,纳入260例III/IVA-B期头颈鳞癌患者,均接受根治性器官保留治疗。
  • 分析治疗前外周血MCV、血小板计数、血红蛋白浓度和白蛋白浓度,采用多因素分析校正混杂因素后评估生存结局。

主要发现

  • 校正潜在混杂因素后,低血红蛋白患者死亡风险是正常血红蛋白者的3.3倍(95%CI 2.26-4.81)。
  • 校正潜在混杂因素后,MCV升高患者死亡风险增加1.54倍(95%CI 1.06-2.24),且独立于部位、分期和HPV状态。
  • MCV对总生存和无进展生存的影响仅限于治疗前血红蛋白正常的患者。
  • 治疗前血小板计数或白蛋白浓度与生存无关联。

临床怎么用

  • 在HNSCC器官保留治疗前,应关注血红蛋白和MCV,辅助预后分层。
  • 对血红蛋白正常但MCV升高的患者,需警惕不良预后。

局限性

  • 回顾性研究设计。
  • 证据等级为III级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mean corpuscular volume (MCV) has been shown in to be a reliable prognostic marker in other cancers; however, no evidence exists on its use in head and neck squamous cell carcinoma (HNSCC). This study aimed to investigate the association between MCV, hemoglobin, platelet count and albumin concentration, and survival in stage III/IVA-B HNSCC treated with concurrent chemoradiotherapy. STUDY DESIGN: Retrospective cohort study. METHODS: In this multicenter retrospective study, we analyzed MCV, platelet count, hemoglobin concentration, and albumin concentration in peripheral blood samples from 260 patients with HNSCC undergoing organ preservation treatment with curative intent at the time of diagnosis. We then analyzed survival outcomes after accounting for confounders using multivariate analysis. RESULTS: After adjustment for potential confounders, patients with low hemoglobin had a 3.3-fold higher risk of death (95% confidence interval [CI]: 2.26-4.81) than those with normal hemoglobin. Patients with an elevated MCV had a 1.54-fold higher risk of death (95% CI: 1.06-2.24), independent of site, stage, and human papillomavirus status. Interestingly, the effect of MCV on overall and progression-free survival was limited to those with a normal pretreatment hemoglobin. We identified no associations between pretreatment platelet count or albumin concentration and survival. CONCLUSION: These findings suggest that pretreatment anemia and macrocytosis are independent predictors of lower overall and progression-free survival in HNSCC patients undergoing organ preservation treatment. LEVEL OF EVIDENCE: III Laryngoscope, 131:E836-E843, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Borsetto D, Polesel J, Tirelli G, et al. Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. Laryngoscope. 2020. PMID: 32589769. doi:10.1002/lary.28882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。